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were excluded. We validated the new Baveno VI recommen-
dation and explored alternative cutoffs.  Results: Ninety-sev-
en patients were analyzed, 76.3% (74/97) male, mean age 
54.3 ± 11.2 years. Most patients (55.7%) had no varices and 
14.4% had varices requiring treatment. Most patients (78.4%) 
had cirrhosis related to chronic hepatitis C. If the new Baveno 
VI recommendation had been applied to this cohort, upper 
endoscopy would have been avoided in 11.3% (11/97) of pa-
tients, none of them with esophageal varices requiring treat-
ment: specificity 100%, sensitivity 13.3%, positive predictive 
value 100%, and negative predictive value 16.3% for ab-
sence of varices requiring treatment. If screening endoscopy 
had been avoided in those patients with liver stiffness <30 
kPa and platelet count  ≥ 120,000, endoscopy would have 
been avoided in 27.8% (27/97) of patients, none of whom 
with esophageal varices requiring treatment: specificity 
100%, sensitivity 32.5%, positive predictive value 100%, and 
negative predictive value 20% for absence of varices requir-
ing treatment.  Conclusions: The new Baveno VI criteria iden-
tified compensated cirrhotic patients without varices requir-
ing treatment in whom screening endoscopy could have 
been avoided safely. Further studies are needed to confirm 
these findings and potentially explore more ambitious but 
still safe cutoffs for those criteria. 
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 Abstract 
 Introduction: Recent studies assessed the predictive value 
of liver transient elastography, combined or not with plate-
let count, for the presence of esophageal varices in patients 
with liver cirrhosis, and multiple cutoffs have been proposed. 
The Baveno VI consensus states that patients with compen-
sated advanced chronic liver disease, liver stiffness <20 kPa, 
and a platelet count >150,000 have a very low risk of having 
varices requiring treatment and can avoid screening endos-
copy. We aimed to validate this recommendation in a cohort 
of cirrhotic patients.  Methods: Retrospective analysis of all 
patients evaluated at the Gastroenterology Department 
(Centro Hospitalar de Lisboa Central) between September 
2009 and October 2015 with a liver stiffness (FibroScan ® ) 
compatible with liver cirrhosis as well as upper endoscopy 
and blood tests within 12 months from elastography. Pa-
tients on propranolol  ≥ 80 mg/day or carvedilol  ≥ 12.5 mg/
day, as well as those with previous variceal bleeding, vari-
ceal endoscopic treatments, or cirrhosis decompensations 
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 Recomendação de Baveno VI Sobre Evicção da 
Endoscopia de Rastreio em Doentes com Cirrose:
Já Lá Estamos? 
 Palavras Chave 
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portal · Varizes esofágicas e gástricas · Técnicas de 
imagem por elasticidade 
 Resumo 
 Introdução: Estudos recentes avaliaram o valor preditivo 
da elastografia hepática transitória, combinada ou não 
com contagem plaquetária, para a presença de varizes 
esofágicas em doentes com cirrose hepática, e foram 
propostos vários valores de corte. O consenso de Baveno 
VI afirma que doentes com doença hepática crónica 
avançada compensada, elastografia hepática <20 kPa e 
>150,000 plaquetas têm muito baixo risco de varizes 
com necessidade de tratamento, podendo evitar endos-
copia de rastreio. Pretendemos validar esta recomenda-
ção numa coorte de doentes cirróticos. Métodos: Análise 
retrospectiva dos doentes avaliados no Serviço de Gas-
trenterologia (Centro Hospitalar de Lisboa Central) entre 
Setembro 2009 e Outubro 2015 com elastografia hepá-
tica (FibroScan ® ) compatível com cirrose hepática e aná-
lises num intervalo até 12 meses desde a elastografia. 
Doentes sob propranolol  ≥ 80 mg/dia ou carvedilol 
 ≥ 12.5 mg/dia, assim como aqueles com antecedentes 
de hemorragia variceal, tratamento endoscópico de va-
rizes ou descompensação de cirrose foram excluídos. Va-
lidámos a nova recomendação de Baveno VI e explorá-
mos valores de corte alternativos. Resultados: Noventa e 
sete doentes foram analisados, 76.3% (74/97) homens, 
idade média 54.3 ± 11.2 anos. A maioria dos doentes 
(55.7%) não tinha varizes, 14.4% tinha varizes com indi-
cação para tratamento. A maioria dos doentes (78.4%) 
tinha cirrose relacionada com hepatite C. Se a nova reco-
mendação de Baveno VI tivesse sido aplicada nesta coor-
te, a endoscopia de rastreio teria sido evitada em 11.3% 
(11/97) dos doentes, nenhum com varizes com indica-
ção para tratamento: especificidade 100%, sensibilidade 
13.3%, valor preditivo positivo 100% e valor preditivo 
negativo 16.3% para ausência de varizes com indicação 
para tratamento. Se a endoscopia de rastreio fosse evi-
tada nos doentes com elastografia hepática <30 kPa e 
>120,000 plaquetas, teria sido evitada em 27.8% (27/97) 
destes doentes, nenhum com varizes com indicação 
para tratamento: especificidade 100%, sensibilidade 
32.5%, valor preditivo positivo 100% e valor preditivo 
negativo 20% para ausência de varizes com indicação 
para tratamento. Conclusão: Os novos critérios de Bave-
no VI identificaram doentes com cirrose compensada e 
sem varizes com indicação para tratamento, em que se 
podia ter evitado com segurança a endoscopia de ras-
treio. São necessários mais estudos para confirmar estes 
resultados e explorar valores de corte mais ambiciosos, 
mas seguros.  © 2016 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel 
 Introduction 
 Portal hypertension is a progressive complication
of liver cirrhosis, and varices and variceal bleeding are 
its most direct consequences  [1] . Gastroesophageal var-
ices are present in approximately 50% of cirrhotic pa-
tients, and their existence correlates with severity of dis-
ease. The most important complication of varices is var-
iceal bleeding, occurring in 25–40% of patients with 
cirrhosis  [2] and associated with around 15% mortality 
 [3] . The risk of variceal bleeding depends on several fac-
tors, including size and appearance of varices and cir-
rhosis stage  [1] . Therefore, patients with varices with 
high-risk features should be identified, so that treat-
ment (primary prophylaxis of variceal bleeding) may be 
initiated.
 Until recently, all clinical guidelines recommended 
that every cirrhotic patient should be screened for varices 
with the gold standard – upper gastrointestinal endos-
copy  [1, 4] , and a recent guideline on noninvasive tests for 
liver disease highlighted that upper endoscopy cannot be 
replaced by noninvasive methods  [5] . 
 Nevertheless, several studies on the prediction of clin-
ically significant portal hypertension (CSPH) with non-
invasive methods have been performed recently, and the 
report from the Baveno VI Consensus Workshop (held 
on April 2015) states that patients with compensated ad-
vanced chronic liver disease with a liver stiffness <20 kPa 
and a platelet count >150,000 have a very low risk of hav-
ing varices requiring treatment and can avoid screening 
endoscopy  [6] .
 We aimed to validate this new Baveno VI recommen-
dation in a cohort of cirrhotic patients.
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 Materials and Methods 
 We performed a retrospective, single-center analysis of all pa-
tients evaluated at the Gastroenterology Department of the Centro 
Hospitalar de Lisboa Central between September 2009 and Octo-
ber 2015 with liver stiffness compatible with liver cirrhosis (>12.5 
kPa) and upper endoscopy as well as platelet count performed 
within 12 months from liver stiffness evaluation.
 All evaluations were performed at the Centro Hospitalar de 
Lisboa Central (liver stiffness evaluation and upper gastrointesti-
nal endoscopy at the Gastroenterology Department, platelet count 
at the Central Laboratory). Liver stiffness was evaluated with tran-
sient elastography (FibroScan ® model 502, Echosens ® , Paris, 
France), performed by experienced users, and validated according 
to current recommendations. Upper endoscopy was performed by 
experienced endoscopists, and esophageal varices were classified 
as small (comprising grade I/small varices) or large (comprising 
grade II/medium and grade III/large varices)  [1] . Patient records 
were reviewed for cirrhosis etiology and stage, as well as past and 
current treatments.
 Patients on treatment for portal hypertension (propranolol 
 ≥ 80 mg/day or carvedilol  ≥ 12.5 mg/day), as well as patients with 
previous variceal bleeding or treatments (such as banding or scle-
rosis) were excluded. Decompensated cirrhotic patients (with as-
cites, hepatic encephalopathy, Child-Pugh class B, or Child-Pugh 
class C) were excluded as well.
 Esophageal varices requiring treatment were defined, accord-
ing to Baveno VI, as small varices with red signs or large varices 
 [6] .
 Statistical analysis was performed with Microsoft Office Excel ® 
2010 and STATA ® v12.1. Descriptive univariate analysis was per-
formed and is reported as means and standard deviations for con-
tinuous variables and proportions for categorical variables.
 Results 
 A total of 97 patients were analyzed, 76.3% (74/97) 
male, with a mean age of 54.3 ± 11.2 years at liver elastog-
raphy. Most patients (55.7%) had no varices, 29.9% had 
small varices without red signs, 1.0% had small varices 
with red signs, and 13.4% had large varices – therefore, 
14.4% (14 patients) had varices requiring treatment. All 
patients were Child-Pugh class A, and most (78.4%) had 
cirrhosis related to chronic hepatitis C. Population char-
acteristics are detailed in  Table 1 .
 If the new Baveno VI recommendation had been ap-
plied to this cohort of cirrhotic patients, upper endoscopy 
would have been avoided in 11.3% (11/97) of patients, 
none of them with esophageal varices requiring treatment 
(2 patients had small varices without red signs and 9 pa-
tients had no varices). Upper endoscopy would have been 
performed in 88.7% (86/97) of patients – 52.3% (56/86) 
of whom had no varices – and would have identified all 
patients with varices requiring treatment.
 The Baveno VI criteria had a specificity of 100% (95% 
CI 76.8–100%), a sensitivity of 13.3% (95% CI 6.81–
22.5%), a negative likelihood ratio of 0.87 (95% CI 0.80–
0.94), a positive predictive value of 100% (95% CI 71.5–
100%), and a negative predictive value of 16.3% (95% CI 
9.2–25.8%) for absence of varices requiring treatment.
 From this cohort, it is possible to generate alternative 
criteria based on liver elastography and platelet count to 
identify patients without varices requiring treatment. If 
screening endoscopy had been avoided in those patients 
with liver stiffness <30 kPa and platelet count  ≥ 120,000, 
 Table 1.  Patient characteristics
All patients
(n = 97)
Without varices
(n = 54)
 With varices (n = 43)
Small, no red
signs (n = 29)
Small, with
red signs (n = 1)
Large (n = 13)
Male gender 74 (76.3) 44 (81.5) 25 (86.2) 0 (0.0) 5 (38.5)
Age at FibroScan®, years 54.3±11.2 55.7±9.9 50.6±12.1 76 55.4±12.0
Liver stiffness, kPa 30.9±17.7 24.7±12.5 38.7±21.0 29.9 39.8±19.6
Platelet count, ×109/mm3 120.8±56.7 141.9±51.9 91.8±45.5 40 104.3±64.2
Liver disease
Hepatitis C 76 (78.4) 41 (75.9) 23 (79.3) 1 (100.0) 11 (84.6)
Alcohol 8 (8.2) 6 (11.1) 1 (3.4) 0 (0.0) 1 (7.7)
Hepatitis B 3 (3.1) 3 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
Cholestatic 3 (3.1) 2 (3.7) 0 (0.0) 0 (0.0) 1 (7.7)
Other 7 (7.2) 2 (3.7) 5 (17.2) 0 (0.0) 0 (0.0)
 Values are n (%) or mean ± standard deviation.
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endoscopy would have been avoided in 27.8% (27/97) of 
patients, none of whom with esophageal varices requiring 
treatment (3 patients had small varices without red signs 
and 24 patients had no varices). Screening endoscopy 
would have been performed in 61.9% patients and would 
have identified all patients in the cohort with varices re-
quiring treatment.
 This new criteria (avoiding screening endoscopy when 
liver stiffness <30 kPa and platelet count  ≥ 120,000) in this 
derivation cohort had a specificity of 100% (95% CI 76.8–
100%), a sensitivity of 32.5% (95% CI 22.6–43.7%), a neg-
ative likelihood ratio of 0.68 (95% CI 0.58–0.78), a posi-
tive predictive value of 100% (95% CI 87.2–100%), and a 
negative predictive value of 20.0% (95% CI 11.4–31.3%) 
for absence of varices requiring treatment.
 Discussion 
 There is a clear potential of noninvasive methods to 
identify cirrhotic patients with low risk of having varices 
requiring treatment and that therefore could avoid un-
pleasant screening endoscopies – relatively invasive pro-
cedures with associated risks and costs.
 Liver stiffness has been shown to correlate with he-
patic venous pressure gradient (HVPG)  [7] . Many studies 
assessed the predictive value of liver elastography (alone 
 [8] or in combination with other noninvasive measures) 
 [9, 10] and platelet count  [11–13] for CSPH. Neverthe-
less, several different surrogate markers of CSPH have 
been used in those studies (i.e., HVPG, presence of vari-
ces, presence of large varices), and their results may not 
be directly comparable.
 In general, proposed cutoffs for liver stiffness predict 
presence and size of esophageal varices with high sensi-
tivities but rather unsatisfactory specificities  [5] . In fact, it 
is probable that liver stiffness performs much better at rul-
ing out varices than ruling them in. Correlation between 
liver stiffness and HVPG is excellent for HVPG values 
lower than 10–12 mm Hg, but is suboptimal for higher 
HVPG values  [14] . This is explained by the fact that with 
cirrhosis progression, the mechanisms of portal hyperten-
sion become less dependent on the intrahepatic resistance 
to portal flow due to tissue fibrosis (measured by liver elas-
tography) and progressively more dependent on extrahe-
patic factors, such as hyperdynamic circulation and 
splanchnic vasodilation  [5] . Therefore, liver stiffness may 
probably perform better at identifying patients without 
varices (i.e., with HVPG below 10–12 mm Hg)  [1] than at 
identifying patients with large varices, or varices with red 
signs, the latter presumably having HVPG values that do 
not correlate well with liver stiffness values.
 The 2015 Baveno VI Consensus Workshop published 
the first consensus recommendation on avoidance of 
screening endoscopy in patients with compensated ad-
vanced liver disease in an era where evidence in this field 
was probably not robust enough. The concept of “com-
pensated advanced chronic liver disease” is, per se, inno-
vative, and may be suspected based on liver transient elas-
tography evaluation: values between 10 and 15 kPa are 
suggestive and values >15 kPa are highly suggestive of 
compensated advanced chronic liver disease. Further-
more, this new concept and its definition are independent 
of the etiology of liver disease  [6] .
 In our study, we found that Baveno VI criteria identi-
fied correctly patients without varices requiring treat-
ment and would have allowed safe avoidance of screening 
endoscopy in 11% of this cohort of compensated cirrhot-
ic patients. Nevertheless, robust data on this issue are 
lacking. It is possible that less stringent criteria will allow 
to safely avoid a greater proportion of screening endosco-
pies in low-risk patients in the future, rendering this man-
agement strategy even more cost-effective. The new cri-
teria generated from this cohort are speculative and not 
generalizable, but demonstrate that further cutoffs may 
be explored.
 Our study has several limitations, and our results 
should be interpreted carefully. This was a single-center, 
retrospective study, based on liver stiffness measures and 
endoscopies performed by different operators (although 
all of them were experienced). Liver stiffness measures 
were based on single determinations and not confirmed, 
as recently proposed  [6] . A liver stiffness cutoff  ≥ 12.5 kPa 
 [15] was used to define liver cirrhosis irrespective of the 
etiology of liver disease. Indeed, alternative cutoffs for 
nonviral liver diseases are insufficiently validated  [5] , and 
even for alcohol-related liver disease, presumably associ-
ated with higher transient elastography values  [5] , the 
proposed cutoff for cirrhosis is 12.5 kPa  [16] . Further-
more, the Baveno VI criteria do not recommend differen-
tial cutoffs for diagnosis of “compensated advanced 
chronic liver disease” according to the etiology of liver 
disease  [6] .
 These Baveno VI criteria performed similarly well 
(negative predictive value 100%) in some studies  [17–19] , 
but failed to identify few patients with varices requiring 
treatment in other ones (negative predictive value 91.2–
98%)  [20, 21] . It is important to note that prevalence of 
varices varied between studies, which were therefore 
prone to spectrum bias.
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 In this study, we did not account for the diagnosis of 
other unsuspected diseases (as gastric antral vascular ec-
tasia, peptic ulcer, or gastric cancer) and surrogate mark-
ers of CSPH (as small esophageal varices) in screening 
endoscopies, which obviously would have a significant 
impact on patient management and outcomes.
 Conclusions 
 The Baveno VI criteria based on liver stiffness (<20 
kPa) and platelet count (>150,000) identified correctly 
compensated cirrhotic patients without varices requiring 
treatment in this cohort (in whom screening endoscopy 
could have been safely avoided), but allowed for avoid-
ance of endoscopy only in a small proportion of patients. 
Further studies, with larger sample sizes, less heteroge-
nous cirrhosis etiologies, and preferentially prospective 
design, are needed to confirm these findings and poten-
tially explore more robust and cost-effective cutoffs for 
liver stiffness and platelet count.
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